ADCT vs. BCYC, CVAC, MRVI, DNTH, LENZ, CRMD, SION, ORGO, ABUS, and SANA
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Bicycle Therapeutics (BCYC), CureVac (CVAC), Maravai LifeSciences (MRVI), Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), CorMedix (CRMD), Sionna Therapeutics (SION), Organogenesis (ORGO), Arbutus Biopharma (ABUS), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs.
ADC Therapeutics (NYSE:ADCT) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.
ADC Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 426.32%. Bicycle Therapeutics has a consensus price target of $29.14, indicating a potential upside of 229.30%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ADC Therapeutics is more favorable than Bicycle Therapeutics.
ADC Therapeutics has a net margin of -300.00% compared to Bicycle Therapeutics' net margin of -450.64%. ADC Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.
In the previous week, ADC Therapeutics and ADC Therapeutics both had 4 articles in the media. Bicycle Therapeutics' average media sentiment score of 1.13 beat ADC Therapeutics' score of 0.42 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.
Bicycle Therapeutics received 81 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 70.50% of users gave Bicycle Therapeutics an outperform vote while only 68.18% of users gave ADC Therapeutics an outperform vote.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Bicycle Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADC Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Summary
Bicycle Therapeutics beats ADC Therapeutics on 9 of the 17 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy ADCT Stock Free ADCT Stock Alerts